Tests radiation to the para-aortic lymph nodes in locally advanced cervical cancer
Tests extra radiation to nearby lymph nodes alongside chemoradiation in women with cervical cancer.
Plain-language title generated from the registry record
Registry title: Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
Key facts
- Where
- Hangzhou, Jinhua, Lishui, Ningbo, Taizhou, and Wanzhou, ChinaSee the 7 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with locally advanced cervical cancer whose scans show cancer in the pelvic lymph nodes but not in the common iliac or para-aortic nodes.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- Squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of the cervix, FIGO 2009 stage IB2 to IVA. PET-CT must show positive pelvic lymph nodes and negative common iliac and para-aortic lymph nodes.
- Earlier treatment
- People who have already received anti-tumor treatment cannot join. People who had radiotherapy for a pelvic malignant tumor or pelvic artery embolization cannot join.
Main reasons for not taking part
- Uncontrolled severe infection
- Another cancer needing treatment, or newly diagnosed, within 5 years
- HIV positive or other immunodeficiency disease
- Liver cirrhosis, decompensated liver disease, chronic kidney insufficiency or kidney failure
- Heart attack, severe arrhythmia or congestive heart failure grade 2 or more
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04974346, who can take part
Where in China
- Zhejiang Cancer HospitalHangzhou, ChinaTaking people
- The First Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
- Jinhua Municipal Central Hospital Medical GroupJinhua, ChinaNo longer taking part
- Lishui People's HospitalLishui, ChinaNo longer taking part
- Ningbo First HospitalNingbo, ChinaNo longer taking part
- Taizhou Central HospiatlTaizhou, ChinaNo longer taking part
- Chongqing University Three Gorges HospitalWanzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zhejiang Cancer Hospital
- Trial code
- NCT04974346
- Record updated
- 25 January 2022
- Original description
Para-aortic lymph node metastasis is a poor prognostic factor for locally advanced cervical cancer, but false negative diagnosis is easy to occur. The aim of this trial was to investigate whether para-aortic prophylactic radiotherapy improves disease-free survival in patients with positive pelvic lymph nodes below the common iliac artery.Read full original descriptionShow less
Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer: a Prospective, Randomized, Multicenter Study
Para-aortic lymph node metastasis is a poor prognostic factor for locally advanced cervical cancer, but false negative diagnosis is easy to occur. The aim of this trial was to investigate whether para-aortic prophylactic radiotherapy improves disease-free survival in patients with positive pelvic lymph nodes below the common iliac artery.
Inclusion: The patients voluntarily participated in the study and signed the informed consent; 18-75 female; Cervical squamous cell carcinoma / adenocarcinoma / adenosquamous cell carcinoma; According to International Federation of Gynecology and Obstetrics(FIGO) 2009 stage, stage ⅠB2 - ⅣA with positive pelvic lymph nodes and negative common iliac and paraaortic lymph nodes diagnosed by PET-CT; Cisplatin chemotherapy is acceptable; Eastern Cooperative Oncology Group(ECOG) score 0-1; The expected survival was more than 6 months; Women of childbearing age must have a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and they are willing to use appropriate contraceptive methods during the test; According to the judgment of the researcher, those who can comply with the trial protocol.
Exclusion: The patient has received anti-tumor treatment; Patients with previous pelvic artery embolization; Previous radiotherapy for pelvic malignant tumor; Uncontrolled severe infection; Combined with other malignant tumor patients who need treatment and / or new diagnosis within 5 years; Liver cirrhosis, decompensated liver disease, chronic renal insufficiency and renal failure; History of immunodeficiency, including HIV positive or other acquired congenital immunodeficiency disease; Myocardial infarction, severe arrhythmia and grade 2 or more congestive heart failure (NYHA classification); There was a history of severe allergic reaction to platinum containing chemotherapy drugs; Complications, need to be taken during the treatment of liver and kidney function damage drugs, such as tuberculosis; Patients with accompanying diseases or other special circumstances that seriously endanger the safety of patients or affect the completion of the study; The patients who could not understand the content of the experiment and could not cooperate and refused to sign the informed consent.